Seaport Therapeutics Launches with $100 Million Oversubscribed …

BOSTON, April 9, 2024 – Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million …


Install CouponFollow Chrome Extension   CouponFollow Extension

$100
OFF

Seaport Therapeutics Launches With $100 Million Oversubscribed …

1 week from now

BOSTON, April 9, 2024 – Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million …

seaporttx.com

$100
OFF

Seaport Therapeu Cs Launches With $100 Million …

1 week from now

Apr 9, 2024  · Seaport Therapeu cs Launches with $100 Million Oversubscribed Series A Financing Round to rSeaport Therapeu cs Launches with $100. ent of Lilly Research …

seaporttx.com

$100
OFF

Seaport Therapeutics Launches With $100 Million

1 week from now

Apr 22, 2024  · After the team behind Karuna Therapeutics sold the firm in December for $14 billion , some members of that same group have started another biotechnology firm developing …

acs.org

$100
OFF

PureTech Launches Seaport Therapeutics With $100 Million …

1 week from now

Apr 9, 2024  · Seaport Therapeutics ("Seaport"), the latest Founded Entity to be created by PureTech, today announced that it has raised $100 million ii in an oversubscribed Series A …

yahoo.com

$100
OFF

Seaport Therapeutics On LinkedIn: Seaport Therapeutics Launches …

1 week from now

We’re pleased to launch Seaport Therapeutics today with the closing of a $100 million oversubscribed Series A financing round, co-led by ARCH Venture Partners, Sofinnova …

linkedin.com

$100
OFF

Seaport Therapeutics Receives $100 Million In Funding To Maximise ...

1 week from now

Apr 11, 2024  · Seaport Therapeutics receives $100 million in funding to maximise Monash invention 11 April 2024 Seaport Therapeutics, a clinical-stage biopharmaceutical company …

monash.edu

$100
OFF

PureTech Launches Seaport Therapeutics With $100 Million …

1 week from now

Apr 9, 2024  · Seaport Therapeutics (“Seaport”), the latest Founded Entity to be created by PureTech, today announced that it has raised $100 million in an oversubscribed Series A …

pharmiweb.com

$100
OFF

Seaport Completes Spin-Off From PureTech And Raises $100 …

1 week from now

Apr 10, 2024  · WilmerHale represented Seaport Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing novel neuropsychiatric medicines, in connection with its spin …

wilmerhale.com

$100
OFF

Seaport Therapeutics Launches With $100 Million Oversubscribed …

1 week from now

Apr 10, 2024  · BOSTON - Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced the closing of a $100 million …

marketscreener.com

$100
OFF

Ex-Karuna Team Launch Seaport With $100m For Psychiatry Meds

1 week from now

5 days ago  · Seaport emerges with $100 million in funding from a Series A – backed by ARCH Venture Partners, Sofinnova Investments, and Third Rock Ventures – which will be used to …

pharmaphorum.com

$100
OFF

Seaport Therapeutics Launches With $100 Million To Develop New …

1 week from now

Apr 9, 2024  · Seaport Therapeutics has $100 million to develop new ways to treat mental disorders. By Jonathan Saltzman Globe Staff, Updated April 9, 2024, 1:35 p.m. 2. The …

bostonglobe.com

$100
OFF

Seaport Therapeutics Launches With $100 Million Oversubscribed …

1 week from now

Apr 9, 2024  · Seaport closes $100 million Series A financing & appoints Daphne Zohar as Founder, CEO & Board Member, & Steven Paul, M.D., as Founder & Board Chair.

businesswire.com

$100
OFF

Seaport Therapeutics Launches With $100 Million ... - BioSpace

1 week from now

Apr 9, 2024  · BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, today …

biospace.com

$100
OFF

Seaport Debuts With $100M Series A, As Psychiatric Boom Grows

1 week from now

Apr 9, 2024  · The new company will be led by Daphne Zohar, the founding CEO of the biotech startup foundry PureTech Health, which helped launch both Karuna and Seaport. Seaport …

statnews.com

$100
OFF

Karuna's Captains Set Sail In New Neuropsychiatric Biotech

1 week from now

Apr 9, 2024  · The oversubscribed $100 million series A round was co-led by Arch Venture Partners and Sofinnova Investments, with Third Rock Ventures and PureTech Health also …

fiercebiotech.com

$100
OFF

ALS-focused Trace Neuroscience Launches With $100 Million In …

1 week from now

6 days ago  · Trace Neuroscience, founded in January, has launched with $101 million raised in a series A financing round to advance its antisense oligonucleotide therapy (ASO) treatment for …

acs.org

$100
OFF

C Ray Therapeutics Completes Over $100 Million Series A

1 week from now

12 hours ago  · CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as "C Ray"), an innovative enterprise …

prnewswire.com

$100
OFF

Seaport Therapeutics Launches With $100 Million Oversubscribed …

1 week from now

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines. Share This Article. ... Seaport Therapeutics is a …

vcaonline.com

FAQs about Seaport Therapeutics Launches with $100 Million Oversubscribed … Coupon?

What has happened to Seaport Therapeutics?

Seaport Therapeutics, a clinical-stage biopharmaceutical company in neuropsychiatry, announced the closing of a $100 million oversubscribed Series A financing round. ...

Who are the cofounders of seaport Therapeutics?

The cofounders of Seaport Therapeutics, (L-R), Michael Chen, Steve Paul and Daphne Zohar. Seaport Therapeutics ...

Is seaport working on a new antidepressant?

A phase 2a trial has validated this proof of concept, said Seaport, which hopes to develop SPT-300 as a treatment for anxious depression. Seaport is also working on SPT-320, a prodrug of agomelatine—an antidepressant available in Europe as Valdoxan but not approved by the FDA. ...

Who is the CEO of seaport?

Seaport will be led by Daphne Zohar along with Founder Steven M. Paul, M.D., who is the former Chief Executive officer of Karuna Therapeutics ("Karuna"), another CNS-focused PureTech Founded Entity that was recently acquired by Bristol Myers Squibb for $14 billion. ...

Is seaport a prodrog?

The other candidate Seaport name-checked in the release is also a prodrog, this time a non-hallucinogenic neuroplastogen being developed for the treatment of mood and other neuropsychiatric disorders. The company also alluded to various discovery and preclinical-stage programs it has in the works. ...

Does Seaport have a glyph platform?

Seaport is also working on SPT-320, a prodrug of agomelatine—an antidepressant available in Europe as Valdoxan but not approved by the FDA. The company hopes its Glyph platform can lower the dose needed for the drug’s effectiveness by reducing its metabolism in the liver and therefore removing the need for liver function monitoring. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension